Clinical Trial Update: Assessment of the Efficacy and Safety of FlutiForm® pMDI 125/5 µg (2 Puffs Bid) Versus Symbicort® Turbohaler® 200/6 µg (2 Puffs Bid) in Adolescent and Adult Subjects With Moderate to Severe Persistent, Reversible Asthma [Phase 3]

View source ↗

Summary

Phase 3 trial comparing FlutiForm pMDI 125/5 µg to Symbicort Turbohaler 200/6 µg in adolescents and adults with moderate to severe persistent, reversible asthma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• FlutiForm (fluticasone propionate/formoterol)
• Symbicort (budesonide/formoterol)

Snippet

Sponsor: Mundipharma Research Limited | Conditions: Asthma | Phase 3 | Status: COMPLETED